LEXINGTON, Mass. , June 1, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau , chief executive officer of LogicBio, will participate in virtual fireside chats at the following upcoming investor conferences:
- Jefferies Virtual Healthcare Conference, Friday, June 4, at 9:30 AM ET .
- JMP Securities Life Sciences Conference, Wednesday, June 16 , at 2:00 PM ET .
Where applicable, live webcasts of the fireside chats can be accessed through the Investors section of the Company's website at https://investor.logicbio.com .
About LogicBio Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The Company's proprietary GeneRide™ platform is a new approach to precise gene insertion that has the potential to harness a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit https://www.logicbio.com/ , which does not form a part of this release.
Media Contacts:
Adam Daley
Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
adaley@berrypr.com
Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com
Investor Contacts:
Matt Lane
Gilmartin Group
(617) 901-7698
matt@gilmartinir.com
View original content: http://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-upcoming-investor-conferences-301303288.html
SOURCE LogicBio Therapeutics, Inc.
